12 Month Price Forecast For OSUR
Distance to OSUR Price Forecasts
OSUR Price Momentum
🤔 Considering OraSure (OSUR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 8:44 PM UTC
OSUR Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, OSUR has a consensus that is neutral. The median price target is $5.00, with forecasts ranging from $4.00 to $9.00. Currently, there are 1 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
With OSUR currently trading at $3.92, the median price forecast suggests a 27.6% upside. The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 129.6% upside, while at provides the most conservative target, suggesting a 2.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OSUR Analyst Consensus
OSUR Price Target Range
Latest OSUR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OSUR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 7, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $5.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $4.50 |
| May 13, 2024 | JP Morgan | Casey Woodring | Neutral | Maintains | $6.00 |
| Apr 4, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $6.50 |
| Feb 29, 2024 | JP Morgan | Neutral | Maintains | $0.00 | |
| Dec 11, 2023 | Citigroup | Patrick Donnelly | Buy | Maintains | $9.00 |
| Nov 8, 2023 | JP Morgan | Tycho Peterson | Neutral | Maintains | $5.00 |
| Jul 17, 2023 | Stephens & Co. | Equal-Weight | Maintains | $5.00 | |
| May 11, 2022 | Citigroup | Patrick Donnelly | Buy | Maintains | $10.00 |
| Feb 24, 2022 | Citigroup | Patrick Donnelly | Buy | Maintains | $12.00 |
| Sep 22, 2021 | Raymond James | Market Perform | Downgrade | $0.00 | |
| Aug 4, 2021 | Raymond James | Andrew Cooper | Outperform | Maintains | $12.50 |
| Jun 28, 2021 | Raymond James | Andrew Cooper | Outperform | Maintains | $11.00 |
| May 6, 2021 | Raymond James | Andrew Cooper | Outperform | Maintains | $12.00 |
| Aug 21, 2020 | Evercore ISI Group | Outperform | Initiates | $0.00 | |
| Aug 10, 2020 | JP Morgan | Neutral | Initiates | $0.00 | |
| Aug 10, 2020 | Citigroup | Buy | Initiates | $0.00 | |
| Aug 7, 2020 | Raymond James | Outperform | Upgrade | $0.00 | |
| May 9, 2019 | Canaccord Genuity | Hold | Downgrade | $0.00 | |
| Jul 16, 2018 | Stephens & Co. | Equal-Weight | Downgrade | $0.00 |
Stocks Similar to OraSure Technologies Inc
The following stocks are similar to OraSure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
OraSure Technologies Inc (OSUR) Financial Data
OraSure Technologies Inc has a market capitalization of $292.41M with a P/E ratio of 26.1x. The company generates $224.26M in trailing twelve-month revenue with a 5.1% profit margin.
Revenue growth is -55.2% quarter-over-quarter, while maintaining an operating margin of -14.1% and return on equity of +2.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
OraSure Technologies Inc (OSUR) Company Overview
About OraSure Technologies Inc
Offers diagnostic tests and specimen collection devices.
The company generates revenue by providing a wide range of point-of-care and home diagnostic tests, alongside specimen collection devices. Their products are sold to various markets including clinical laboratories, hospitals, and public health organizations, enabling them to capture diverse revenue streams from healthcare providers and commercial entities.
OraSure Technologies, Inc. was founded in 2000 and is headquartered in Bethlehem, Pennsylvania. It has a strong product portfolio that includes COVID-19 tests, HIV tests, drug testing systems, and microbiome products, positioning it well in the growing health diagnostics sector. The global reach of its products further enhances its market potential.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
638
CEO
Ms. Carrie Eglinton Manner
Country
United States
IPO Year
1992
Website
www.orasure.comOraSure Technologies Inc (OSUR) Latest News & Analysis
New Strong Buy Stocks for January 16th
6 days agoMRCY, BBCP, OSUR, VIK, and IFS were added to the Zacks Rank #1 (Strong Buy) List on January 16, 2025.
Zacks Rank #1 indicates strong bullish sentiment for MRCY, BBCP, OSUR, VIK, and IFS, suggesting potential for price appreciation and favorable investment opportunities.
NOWDiagnostics, Inc. has filed a federal lawsuit against OraSure Technologies for breach of contract and misappropriation of trade secrets, seeking compensatory and punitive damages.
NOWDiagnostics' legal claim against OraSure could impact OraSure's financial stability and reputation, potentially affecting stock performance and investor sentiment.
OraQuick® HIV Self-Test is now approved for adolescents aged 14 and older, expanding access to HIV testing. Previously, it was approved only for those 17 and older.
The expanded age range for the OraQuick® HIV Self-Test can boost sales and market share, reflecting increased demand for healthcare products, positively impacting company valuations.
OraSure Technologies, Inc. (NASDAQ: OSUR) issued a correction regarding their announcement on the OraQuick® HIV Self-Test aimed at improving access to HIV testing for adolescents.
The correction highlights a key product launch by OraSure Technologies, potentially impacting market perception and stock performance due to increased access to HIV testing.
OraSure Technologies, Inc. (NASDAQ: OSUR) will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, at 9:00 a.m. PT.
OraSure's participation in a major healthcare conference can boost visibility, attract investor interest, and potentially influence stock performance through announcements or investor sentiment.
Zacks uses its Rank system, focusing on earnings estimates and revisions, to identify strong stock picks, while also monitoring value, growth, and momentum trends.
Zacks' emphasis on earnings estimates and revisions highlights potential stock performance, guiding investors towards strong picks amid value, growth, and momentum trends.
Frequently Asked Questions About OSUR Stock
What is OraSure Technologies Inc's (OSUR) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, OraSure Technologies Inc (OSUR) has a median price target of $5.00. The highest price target is $9.00 and the lowest is $4.00.
Is OSUR stock a good investment in 2025?
According to current analyst ratings, OSUR has 1 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for OSUR stock?
Wall Street analysts predict OSUR stock could reach $5.00 in the next 12 months. This represents a 27.6% increase from the current price of $3.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is OraSure Technologies Inc's business model?
The company generates revenue by providing a wide range of point-of-care and home diagnostic tests, alongside specimen collection devices. Their products are sold to various markets including clinical laboratories, hospitals, and public health organizations, enabling them to capture diverse revenue streams from healthcare providers and commercial entities.
What is the highest forecasted price for OSUR OraSure Technologies Inc?
The highest price target for OSUR is $9.00 from Patrick Donnelly at Citigroup, which represents a 129.6% increase from the current price of $3.92.
What is the lowest forecasted price for OSUR OraSure Technologies Inc?
The lowest price target for OSUR is $4.00 from at , which represents a 2.0% increase from the current price of $3.92.
What is the overall OSUR consensus from analysts for OraSure Technologies Inc?
The overall analyst consensus for OSUR is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are OSUR stock price projections?
Stock price projections, including those for OraSure Technologies Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
